← All trials
NCT04241315
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 26, 2020
- Primary completion
- Apr 26, 2021
- Completion date
- Aug 1, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 130
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- On Target Laboratories, LLCLead sponsor
- University of PennsylvaniaOverall official - principal investigator
- Clinipace LTDCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.